Mesoblast posts revenue jump and new funding: Key takeaways for investors

The Mesoblast Ltd (ASX: MSB) share price is in focus after the company reported net revenues of US$30 million for the December 2025 quarter, up 60% from the prior period, on the back of strong Ryoncil® sales and new financing arrangements.

What did Mesoblast report?

• Ryoncil® gross sales reached US$35 million, a 60% lift quarter-on-quarter
• Net revenues for the quarter totalled US$30 million
• US$130 million in cash on hand at 31 December 2025
• Net operating cash outflow of US$16 million for the quarter
• Secured a US$125 million non-dilutive credit facility at 8% interest, with an unsecured US$75 million tranche drawn
• No interim dividend declared

What else do investors need to know?

Mesoblast enhanced its financial flexibility this quarter, drawing US$75 million from a new lower-cost debt facility. This replaces more expensive loans and gives the company greater room to fund strategic partnerships as well as potential product expansion.

Clinically, Mesoblast provided positive updates on Ryoncil®’s use in paediatric patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD), as well as progress in extending Ryoncil®’s label to treat adults—an addressable market about three times larger. The company also received constructive feedback from the US FDA regarding its chronic low back pain therapy, with pivotal Phase 3 studies close to completing enrolment.

What did Mesoblast management say?

Mesoblast Chief Executive Dr. Silviu Itescu said:

This quarter was highlighted by continued strong Ryoncil® sales and the establishment of a new lower-cost non-dilutive financing facility both of which enable greater flexibility for strategic partnerships and pursuit of label expansion for Ryoncil®.

What’s next for Mesoblast?

Looking ahead, Mesoblast expects net cash outflows to decline, driven by stable or growing product revenues and tight cost controls. The company aims to complete the pivotal trial for Ryoncil® in adults and finish key patient enrolment in its chronic low back pain program during the next quarter.

Management also flagged its plans to pursue new regulatory submissions and further manufacturing scale-up, as it seeks to establish additional cell therapies for inflammatory conditions. Strategic partnerships and global commercial expansion remain key sections of Mesoblast’s long-term roadmap.

Mesoblast share price snapshot

Over the past 12 months, Mesoblast shares have declined 12%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Mesoblast posts revenue jump and new funding: Key takeaways for investors appeared first on The Motley Fool Australia.

More reading

• Ramelius Resources shares: December 2025 quarterly earnings highlights
• Nickel Industries December 2025 quarter: Strong HPAL margins, mining rebounds
• Liontown earnings: Revenue surges and underground transition completed in Q2 FY26
• Liontown shares in focus as LG Energy Solution swaps $250m debt for equity
• Whitehaven Coal posts strong Q2 production and cost control

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.